Last reviewed 2026-04-23 · How we verify

Low Dose Rifaximin DER

Bausch Health Americas, Inc. · Phase 2 active Small molecule

Low Dose Rifaximin DER is a Antibiotic Small molecule drug developed by Bausch Health Americas, Inc.. It is currently in Phase 2 development for Treatment of hepatic encephalopathy.

Inhibits bacterial RNA synthesis

Inhibits bacterial RNA synthesis Used for Treatment of hepatic encephalopathy.

At a glance

Generic name	Low Dose Rifaximin DER
Sponsor	Bausch Health Americas, Inc.
Drug class	Antibiotic
Target	RNA polymerase
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	Phase 2

Mechanism of action

Rifaximin is a non-absorbable antibiotic that acts by binding to the bacterial RNA polymerase, thereby inhibiting bacterial RNA synthesis.

Approved indications

Treatment of hepatic encephalopathy

Common side effects

Nausea
Diarrhea
Abdominal pain

Key clinical trials

Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Low Dose Rifaximin DER CI brief — competitive landscape report
Low Dose Rifaximin DER updates RSS · CI watch RSS
Bausch Health Americas, Inc. portfolio CI

Frequently asked questions about Low Dose Rifaximin DER

What is Low Dose Rifaximin DER?

Low Dose Rifaximin DER is a Antibiotic drug developed by Bausch Health Americas, Inc., indicated for Treatment of hepatic encephalopathy.

How does Low Dose Rifaximin DER work?

Inhibits bacterial RNA synthesis

What is Low Dose Rifaximin DER used for?

Low Dose Rifaximin DER is indicated for Treatment of hepatic encephalopathy.

Who makes Low Dose Rifaximin DER?

Low Dose Rifaximin DER is developed by Bausch Health Americas, Inc. (see full Bausch Health Americas, Inc. pipeline at /company/bausch-health-americas-inc).

What drug class is Low Dose Rifaximin DER in?

Low Dose Rifaximin DER belongs to the Antibiotic class. See all Antibiotic drugs at /class/antibiotic.

What development phase is Low Dose Rifaximin DER in?

Low Dose Rifaximin DER is in Phase 2.

What are the side effects of Low Dose Rifaximin DER?

Common side effects of Low Dose Rifaximin DER include Nausea, Diarrhea, Abdominal pain.

What does Low Dose Rifaximin DER target?

Low Dose Rifaximin DER targets RNA polymerase and is a Antibiotic.

Drug class: All Antibiotic drugs
Target: All drugs targeting RNA polymerase
Manufacturer: Bausch Health Americas, Inc. — full pipeline
Therapeutic area: All drugs in Infectious Disease
Indication: Drugs for Treatment of hepatic encephalopathy
Compare: Low Dose Rifaximin DER vs similar drugs
Pricing: Low Dose Rifaximin DER cost, discount & access